02 Aug 2013, BioSpectrum Bureau , BioSpectrum
New Delhi: Ahead of the Drug Price Control Order (DPCO) to revise drug prices that came into effect on July 29, medicine wholesalers and retailers have warned of many repercussions. The most important matter of worry before this community is that this revision of prices would harm consumers and even the economy of the country.
Only two big companies have so far been provided a stay order by the High Court - Cipla and Sun Pharma, even though the authorities have said that all steps have been taken to prevent any negative fallout.
Traders are now worried about the fate of an estimated $1.69 billion worth of stock. Meanwhile, many drug companies have asked traders about their stocks so that the labels on the packets could be changed. The solution, many traders say, would have been limiting the price for goods manufactured after a certain time, while allowing the existing stocks to be sold at prevailing price.